All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Join our

Treating classical Hodgkin lymphoma: Spotlight on targeted therapies

with Gilles Salles, Paul Bröckelmann, and Ann S. LaCasce

Saturday, November 2, 2024
8:50-9:50 CET

Register now

This independent educational activity is sponsored by Takeda. All content is developed independently by the faculty. Funders are allowed no direct influence on the content of this activity.

  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.

The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene and Roche, and supported through educational grants from Bristol Myers Squibb, Ipsen Biopharmaceuticals, Pfizer, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC. View funders.

2024-08-01T10:51:18.000Z

ESMO guidelines: Interim update on new targeted therapies for CLL

Aug 1, 2024
Share:
Learning objective: After reading this article, learners will be able to cite a new clinical development in CLL.


The European Society for Medical Oncology (ESMO) has released an interim update to their clinical practice guidelines for chronic lymphocytic leukemia (CLL). This update includes new recommendations for targeted therapies for the treatment of first line (1L) and relapsed/refractory (R/R) CLL.


Key learnings:

In the ESMO interim update, the treatment algorithms for first line and relapsed therapy for CLL have been updated.

Key amendments to the guidelines cover:

  • The approval of time-limited ibrutinib plus venetoclax in the first-line setting.
  • New data on minimal residual disease-driven treatment.
  • The approval of zanubrutinib for treating both first-line and R/R CLL.
  • The additional evidence on time-limited venetoclax plus anti-CD20 antibody combination in the first line.
  • Insights on later-line treatments, depending on preceding treatment.

These updates aim to improve patient outcomes by incorporating the latest evidence and treatment options for CLL and aim to help HCPs to tailor therapy based on patient characteristics and response.

  1. Eichhorst B, et al. ESMO Clinical Practice Guideline interim update on new targeted therapies in the first-line and at relapse of chronic lymphocytic leukaemia. Ann Oncol. Online ahead of print. DOI: 10.1016/j.annonc.2024.06.016.

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Your opinion matters

HCPs, what is your preferred format for educational content on the Lymphoma Hub?
20 votes - 11 days left ...

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox